A number of research firms have changed their ratings and price targets for Pacira Pharmaceuticals (NASDAQ: PCRX):

  • 8/29/2017 – Pacira Pharmaceuticals had its price target lowered by analysts at Canaccord Genuity from $56.00 to $48.00. They now have a “buy” rating on the stock.
  • 8/23/2017 – Pacira Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $87.00 price target on the stock.
  • 8/22/2017 – Pacira Pharmaceuticals is now covered by analysts at Needham & Company LLC. They set a “buy” rating and a $55.00 price target on the stock.
  • 8/22/2017 – Pacira Pharmaceuticals had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $53.00 price target on the stock, down previously from $54.00.
  • 8/21/2017 – Pacira Pharmaceuticals was upgraded by analysts at Janney Montgomery Scott from a “sell” rating to a “neutral” rating. They now have a $31.00 price target on the stock.
  • 8/11/2017 – Pacira Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Pacira incurred wider-than-expected loss in second-quarter 2017 and revenues missed estimates. the company efforts to expand Exparel's label to boost sales in oral surgery and chronic pain are encouraging. The company also remains optimistic of its partnership with J&J to market and promote the use of Exparel, with their sales and medical education teams. Going forwad, Pacira is looking to expand Exparel's label in the animal health market as well. Shares of the company have outperformed the industry year to date. However, Pacira’s dependence on its key marketed drug, Exparel, for top-line growth is concerning. A decline in Exparel sales will adversely impact the company's top line.The company also discontinued the production of DepoCyt(e) due to persistent technical issues specific to DepoCyt.”
  • 8/4/2017 – Pacira Pharmaceuticals was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 8/3/2017 – Pacira Pharmaceuticals was given a new $59.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 8/3/2017 – Pacira Pharmaceuticals had its price target lowered by analysts at BMO Capital Markets from $42.00 to $40.00. They now have a “market perform” rating on the stock.
  • 8/2/2017 – Pacira Pharmaceuticals had its “hold” rating reaffirmed by analysts at Cowen and Company.
  • 8/2/2017 – Pacira Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 7/31/2017 – Pacira Pharmaceuticals had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $56.00 price target on the stock.
  • 7/30/2017 – Pacira Pharmaceuticals was given a new $58.00 price target on by analysts at Royal Bank Of Canada. They now have a “buy” rating on the stock.
  • 7/27/2017 – Pacira Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/26/2017 – Pacira Pharmaceuticals had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $54.00 price target on the stock.
  • 7/25/2017 – Pacira Pharmaceuticals was given a new $56.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 7/19/2017 – Pacira Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $87.00 price target on the stock.
  • 7/14/2017 – Pacira Pharmaceuticals had its “hold” rating reaffirmed by analysts at Cowen and Company. They wrote, “Nerve block data for Exparel is anticipated within the next month, and our consultants.””

Shares of Pacira Pharmaceuticals, Inc. (NASDAQ PCRX) traded down 0.26% on Monday, hitting $38.00. The stock had a trading volume of 351,672 shares. Pacira Pharmaceuticals, Inc. has a one year low of $29.95 and a one year high of $58.95. The firm has a 50 day moving average price of $39.71 and a 200 day moving average price of $44.89. The company’s market capitalization is $1.53 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings data on Wednesday, August 2nd. The company reported ($0.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by $0.06. Pacira Pharmaceuticals had a negative net margin of 23.36% and a negative return on equity of 12.44%. The firm had revenue of $70.90 million during the quarter, compared to the consensus estimate of $73.37 million. Pacira Pharmaceuticals’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.21 EPS. On average, equities research analysts predict that Pacira Pharmaceuticals, Inc. will post ($0.16) earnings per share for the current fiscal year.

In other Pacira Pharmaceuticals news, Director Paul J. Hastings sold 1,044 shares of the stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $36.15, for a total transaction of $37,740.60. Following the completion of the transaction, the director now owns 3,518 shares in the company, valued at approximately $127,175.70. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Kristen Marie Williams sold 3,461 shares of the stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $36.75, for a total value of $127,191.75. Following the transaction, the chief accounting officer now owns 21,312 shares of the company’s stock, valued at approximately $783,216. The disclosure for this sale can be found here. In the last quarter, insiders have sold 33,390 shares of company stock valued at $1,215,480. Corporate insiders own 6.60% of the company’s stock.

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Receive News & Stock Ratings for Pacira Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.